Fibrodysplasia Ossificans Progressiva (FOP)

Informatie over Fibrodysplasia Ossificans Progressiva (FOP)

FOP is een uiterst zeldzame genetische ziekte¹ die botvorming buiten het skelet en in de weke delen veroorzaakt..^1,2 . Ipsen benut nieuwe werkingsmechanismen via de ontwikkeling van twee onderzoeksactieve stoffen om mensen met FOP mogelijk een innovatieve behandeling te bieden.

Baujat G, Choquet R, Boueé S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017:12(1):123.
Kaplan FS, Shen Q, Lounev V, et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab. 2008; 26(6):521–30.

ECTS-conferentie 2021 – Ipsen-symposium over FOP

Spotlight op Heterotopic Ossification (HO): betere diagnose en zorg voor patiënten met FOP

Ontdek meer

Materialen en Presentaties

april 17, 2026

Immune-related neurological toxicities – Dr Van Wylick

Niercelcarcinoom, Oncologie, Videos, PDFs & Podcasts
Time: 1 minuut leestijd

Fibrodysplasia Ossificans Progressiva (FOP)

Informatie over Fibrodysplasia Ossificans Progressiva (FOP)

Materialen en Presentaties

Immune-related neurological toxicities – Dr Van Wylick

How do we deal with irAE and dysimmunity populations who need ICI in Belgium – Prof Aspeslagh

Immunotherapy-Induced hypophysitis: diagnosis, challenges, and therapeutic strategies – Dr Martens

How to handle challenging TKI toxicities? – Prof Seront

Upcoming therapeutic advances – Prof Rottey

Belgian fellow-led present: HBOC germline mut. and efficacy of ICI (BEL-RCC2 study) – Dr Vrijders

Belgian fellow-led present: TKI-related tox. marker as therapy resp. predictor in mRCC – Dr Vermassen

Belgian fellow-led presentations: Optimal treatment of brain metastases in RCC – Dr Roodhooft

Belgian fellow-led presentations: Role of eosinophils in clear-cell renal cell carcinoma – Dr Gilon

nccRCC – understanding the new classification and guiding treatment decisions – Prof. Verbiest

Real cases, real strategies Masterclass in action: interactive case discussions – Prof. Gennigens, Prof. Martinez, Prof. Seront

The evolving role of biomarkers: from concept to clinical impact – Prof. Rottey

The con’s of adjuvant therapy – Prof. Gennigens

The pro’s of adjuvant therapy – Prof. Beuselinck

Debulking surgery in metastatic RCC: benefits and limitations – Prof. Van Praet

Optimizing radiation therapy in RCC: Expert insights and best practices – Prof. Berghen

Current landscape of first-line treatment in mRCC – Dr. Carril

The debate on IO treatment duration: current evidence and future directions – Dr. Decruyenaere

2L and beyond: treatment strategies post IO/IO & IO/TKI – Dr. Gizzi

Voel je goed in je lichaam tijdens de hormonale behandeling van prostaatkanker

Je mentaal goed voelen tijdens de hormonale behandeling van prostaatkanker

Hoe omgaan met intieme relaties tijdens de hormonale behandeling van prostaatkanker

Betrek je familie en vrienden erbij tijdens de hormonale behandeling van prostaatkanker

Laten we praten over wat voor jou belangrijk is

Longitudinal goal attainment with repeat injections of abobotulinumtoxinA in adults with lower limb spasticity: AboLiSh Study

Leven met spasticiteit

Wat is spasticiteit

Patiëntengetuigenis

Behandelingsdoelen bespreken met je arts

Omgaan met prikangst

Behandeling van spasticiteit

EAU 2025 Highlights – RCC

EAU 2025 Highlights – Prostate Cancer

EAU 2025 Highlights – Bladder Cancer

ASCO GU 2025 Highlights – RCC

ASCO GU 2025 Highlights – Prostate Cancer

ASCO GU 2025 Highlights – Bladder Cancer

Understanding ALGS: Clinical presentation and symptoms

Understanding PFIC: Clinical presentation and Symptoms

Genetic Cholestasis: Pharmacological treatment options

Liver transplantation for patients with cholestatic liver diseases

Challenges in the diagnosis of adults with cholestatic liver disease

Genetic cholestasis: How to diagnose?

Filmpje voor patiënten over TNM classificatie van prostaatkanker

Primary Biliary Cholangitis (PBC): epidemiology, diagnostic challenges and a shifting treatment paradigm

Podcast – ACRO-talks – Episode 2: Leven met Acromegalie

Podcast – ACRO-talks – Episode 1: Acromegalie in de spotlights

ESMO 2024 highlights – RCC

ESMO 2024 highlights – prostate cancer

ESMO 2024 highlights – blaaskanker

ESPGHAN 2024: PFIC through a different lens – How can you change the course of the disease?

NETtalks – Leven met NET: de stem van de patiënt

NETtalks Episode 7 – First Line Frequencies: walk the talk through NET Diagnosis and Treatment

NETtalks Episode 6 – Echoes of complexity: NET G3/NEC Treatment explored

NETtalks Episode 5 – mTOR Tales: Exploring its role in the NET treatment story

NETtalks Episode 4 – Hormonal Harmony: SSA therapy in focus

NETtalks Episode 3 – Cutting Edge Chronicles: NET Surgery insights

NETtalks Episode 2 – Radiant Waves: Exploring the Breakthroughs of PRRT Treatment in NET (part 2)

NETtalks Episode 1 – Radiant Waves: Exploring the Breakthroughs of PRRT Treatment in NET (part 1)

EAU 2024: Guidelines on Prostate Cancer

Omgaan met injectieangst van uw patiënten

Introduction to NET-talks

Podcast – Dr Jacinto: Goal setting in the treatment of spasticity

Hormonal therapy in prostate cancer care

Precision medicine for prostate cancer (mCRPC)

Screening and early detection of prostate cancer

Radiotherapy highlights in prostate cancer

De Gevolgen – het aanvaarden van spasticiteit

CVA, wat is het?

Behandeling met botulinetoxine type A bij kinderen met spastische cerebrale parese

Wat is er nieuw in de behandeling van urinaire incontinentie met detrusoroveractiviteit ?

Wat is er nieuw in de behandeling van spasticiteit ?

Behandeling van cervicale dystonie met botulinetoxine type A

2022 & ASCO GU’23 Highlights van prostaatkankerchirurgie – Prof. Dr. Steven Joniau

Doelen stellen bij spastische parese

Spasticiteit en multiple sclerose

Behandeling van blefarospasme met botulinetoxine type A